NGM120 is a proprietary, antagonistic antibody binding GFRAL that is designed to inhibit the effects of elevated GDF15 levels in cancer patients. GDF15 is believed to contribute to uncontrolled weight loss in these patients, also known as cancer anorexia and cachexia syndrome, or CACS. We believe that antagonistic antibodies blocking the interaction between GFRAL and GDF15 could provide a novel approach to developing treatments for anorexia, CACS and, potentially, cancer. NGM120 is currently in Phase 1 trials to assess safety, tolerability and pharmacokinetics.
Additional information about NGM’s pioneering work on the biology of GFRAL and its ligand, the human hormone GDF15, can be found here.
Under our collaboration agreement, Merck will have a one-time right to exercise an option to license NGM120 following human proof of concept.